DK2773958T3 - Method for identifying an analyte in a biological sample - Google Patents
Method for identifying an analyte in a biological sample Download PDFInfo
- Publication number
- DK2773958T3 DK2773958T3 DK12790972.9T DK12790972T DK2773958T3 DK 2773958 T3 DK2773958 T3 DK 2773958T3 DK 12790972 T DK12790972 T DK 12790972T DK 2773958 T3 DK2773958 T3 DK 2773958T3
- Authority
- DK
- Denmark
- Prior art keywords
- aptamer
- analyte
- sers
- sam
- dna
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 122
- 239000012472 biological sample Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 25
- 239000013545 self-assembled monolayer Substances 0.000 claims abstract description 102
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 claims abstract description 93
- 239000002094 self assembled monolayer Substances 0.000 claims abstract description 85
- 238000000479 surface-enhanced Raman spectrum Methods 0.000 claims abstract description 84
- 108091023037 Aptamer Proteins 0.000 claims abstract description 78
- 229910052751 metal Inorganic materials 0.000 claims abstract description 17
- 239000002184 metal Substances 0.000 claims abstract description 17
- 239000000523 sample Substances 0.000 claims abstract description 14
- 238000003556 assay Methods 0.000 claims abstract description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 43
- 108091008102 DNA aptamers Proteins 0.000 claims description 24
- 239000010410 layer Substances 0.000 claims description 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000012795 verification Methods 0.000 claims description 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 17
- 230000003595 spectral effect Effects 0.000 abstract description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 229960004134 propofol Drugs 0.000 description 19
- 229910052709 silver Inorganic materials 0.000 description 19
- 239000004332 silver Substances 0.000 description 19
- 229910017745 AgNP Inorganic materials 0.000 description 18
- 230000027455 binding Effects 0.000 description 15
- 238000001069 Raman spectroscopy Methods 0.000 description 14
- 230000003444 anaesthetic effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 12
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 229910052737 gold Inorganic materials 0.000 description 11
- 239000010931 gold Substances 0.000 description 11
- 229920002521 macromolecule Polymers 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 9
- 230000005284 excitation Effects 0.000 description 9
- 201000008827 tuberculosis Diseases 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000304886 Bacilli Species 0.000 description 6
- 241000223960 Plasmodium falciparum Species 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 229940093476 ethylene glycol Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- SDAWVOFJSUUKMR-UHFFFAOYSA-N 12-sulfanyldodecanoic acid Chemical compound OC(=O)CCCCCCCCCCCS SDAWVOFJSUUKMR-UHFFFAOYSA-N 0.000 description 5
- 241001112090 Pseudovirus Species 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108091008103 RNA aptamers Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229940124326 anaesthetic agent Drugs 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 244000052613 viral pathogen Species 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- UGZAJZLUKVKCBM-UHFFFAOYSA-N 6-sulfanylhexan-1-ol Chemical compound OCCCCCCS UGZAJZLUKVKCBM-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- ORTRWBYBJVGVQC-UHFFFAOYSA-N hexadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCS ORTRWBYBJVGVQC-UHFFFAOYSA-N 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004375 physisorption Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KQLXCLJTWNATKC-UHFFFAOYSA-N 11-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]undecane-1-thiol Chemical compound COCCOCCOCCOCCCCCCCCCCCS KQLXCLJTWNATKC-UHFFFAOYSA-N 0.000 description 1
- APOIFWJNLAELBI-UHFFFAOYSA-N 11-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]undecane-1-thiol Chemical compound COCCOCCOCCOCCOCCOCCOCCCCCCCCCCCS APOIFWJNLAELBI-UHFFFAOYSA-N 0.000 description 1
- ULGGZAVAARQJCS-UHFFFAOYSA-N 11-sulfanylundecan-1-ol Chemical compound OCCCCCCCCCCCS ULGGZAVAARQJCS-UHFFFAOYSA-N 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- FASSFROSROBIBE-UHFFFAOYSA-N 2-[2-[2-(11-sulfanylundecoxy)ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCCCCCCCCCCS FASSFROSROBIBE-UHFFFAOYSA-N 0.000 description 1
- IOBMVUDHPRVCSO-UHFFFAOYSA-N 2-[2-[2-[2-(11-sulfanylundecoxy)ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCCCCCCCCCCS IOBMVUDHPRVCSO-UHFFFAOYSA-N 0.000 description 1
- QYKSUHRPPSCIFK-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(11-sulfanylundecoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCCCCCCCCCCS QYKSUHRPPSCIFK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 108700021469 Mycobacterium tuberculosis rpoB Proteins 0.000 description 1
- 229930183781 Mycobactin Natural products 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- -1 N-hydroxysuccinimide (NHS) ester Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- IYRDVAUFQZOLSB-UHFFFAOYSA-N copper iron Chemical compound [Fe].[Cu] IYRDVAUFQZOLSB-UHFFFAOYSA-N 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 238000000289 electrochemical surface enhanced Raman spectroscopy Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 101150079015 esxB gene Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000011898 label-free detection Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- XZGYBQIQSLSHDH-COEJQBHMSA-N mycobactin Chemical compound C1CCCN(O)C(=O)C1NC(=O)C(C)C(CC)OC(=O)C(CCCCN(O)C(=O)\C=C/CCCCCCCCCCCCCCC)NC(=O)C(N=1)COC=1C1=C(C)C=CC=C1O XZGYBQIQSLSHDH-COEJQBHMSA-N 0.000 description 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- HLQGVSDAPGNBGG-ITGKQZKFSA-N phthiocerol A Chemical compound CCCCCCCCCCCCCCCCCC[C@H](O)C[C@H](O)CCCC[C@@H](C)[C@H](CC)OC HLQGVSDAPGNBGG-ITGKQZKFSA-N 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2610/00—Assays involving self-assembled monolayers [SAMs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201108016 | 2011-11-02 | ||
| PCT/IB2012/056108 WO2013065016A1 (en) | 2011-11-02 | 2012-11-02 | A method of detecting and/or quantifying an analyte in a biological sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2773958T3 true DK2773958T3 (en) | 2018-03-12 |
Family
ID=47222168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12790972.9T DK2773958T3 (en) | 2011-11-02 | 2012-11-02 | Method for identifying an analyte in a biological sample |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9518986B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2773958B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104380105B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014010696A2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2773958T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014KN01168A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013065016A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201403386B (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143247A1 (en) * | 2014-03-19 | 2015-09-24 | The Regents Of The University Of Colorado, A Body Corporate | Binding detection using liquid crystal |
| CA2976963A1 (en) * | 2015-02-19 | 2016-08-25 | Ionica Sciences | Reagents and methods for detecting infectious diseases |
| CN105510411B (zh) * | 2015-09-14 | 2018-05-08 | 陕西师范大学 | 基于细胞与微电极的相互作用实现单一癌细胞的检测方法 |
| DE102015220414A1 (de) * | 2015-10-20 | 2017-04-20 | Robert Bosch Gmbh | Propofolsensor zur Messung einer Narkosetiefe |
| CN105277527A (zh) * | 2015-10-29 | 2016-01-27 | 江南大学 | 一种基于拉曼信标分子编码银@金核壳纳米粒子的真菌毒素双重检测方法 |
| KR101816521B1 (ko) * | 2016-01-28 | 2018-01-09 | 광주과학기술원 | 삽입제를 이용한 국소표면플라즈몬공명 기반 고감도 압타머 센서 |
| WO2017142745A1 (en) | 2016-02-17 | 2017-08-24 | The Curators Of The University Of Missouri | Fabrication of multilayer nanograting structures |
| CN109791546A (zh) | 2016-10-28 | 2019-05-21 | 惠普发展公司有限责任合伙企业 | 目标类别特征模型 |
| KR101923196B1 (ko) * | 2017-09-25 | 2018-11-28 | 주식회사 엠디엡투스 | Cfp10에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| US20210190774A1 (en) * | 2017-12-18 | 2021-06-24 | The University Of Memphis Research Foundation | Compositions and methods for the detection and molecular profiling of membrane bound vesicles |
| TWI686599B (zh) * | 2018-05-24 | 2020-03-01 | 國立清華大學 | 塵蟎抗原檢測系統及方法 |
| JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
| WO2020100159A1 (en) * | 2018-11-13 | 2020-05-22 | Translational Health Science And Technology Institute | A novel aptamer and an electrochemical biosensor for the rapid detection and diagnosis of tuberculous meningitis |
| US11988663B2 (en) | 2018-12-18 | 2024-05-21 | The University Of Memphis Research Foundation | Compositions and methods for the detection and molecular profiling of membrane bound vesicles |
| TWI693403B (zh) | 2019-01-17 | 2020-05-11 | 逢甲大學 | 免疫檢測方法 |
| WO2020209796A2 (en) * | 2019-04-09 | 2020-10-15 | Agency For Science, Technology And Research | Label-free detection of mycobacteria using surface enhanced raman spectroscopy |
| CN110907643A (zh) * | 2019-12-02 | 2020-03-24 | 中国科学院重庆绿色智能技术研究院 | 一种大肠杆菌检测芯片的制备方法及检测芯片 |
| WO2021239495A1 (en) * | 2020-05-29 | 2021-12-02 | Somnus Scientific Ltd | A propofol sensor |
| TWI759776B (zh) * | 2020-06-22 | 2022-04-01 | 淡江大學 | 檢測基板、拉曼光譜檢測系統及拉曼光譜檢測方法 |
| CN116368238A (zh) * | 2020-09-24 | 2023-06-30 | 伊诺泰科精密医疗股份有限公司 | 用于检测病原体的系统、设备和方法 |
| CN112240881A (zh) * | 2020-09-30 | 2021-01-19 | 合肥国研汉因检测科技有限公司 | 使用拉曼光谱法快速检测痕量芬太尼的方法 |
| CN112986212B (zh) * | 2021-03-10 | 2023-01-17 | 中国人民解放军海军军医大学 | 一种g-四链体核酸适配体与小分子相互作用的研究方法 |
| CN114577754A (zh) * | 2021-12-24 | 2022-06-03 | 天津大学 | 基于适体变构效应的微型光纤表面等离子共振传感器 |
| CN115711873B (zh) * | 2022-11-09 | 2024-05-28 | 清华大学 | 一种利用sers文件卡片进行定量分析的方法 |
| CN117054389A (zh) * | 2023-07-13 | 2023-11-14 | 淮安市第五人民医院 | 一种用于快速鉴定胃部幽门螺旋杆菌感染的方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376556A (en) | 1989-10-27 | 1994-12-27 | Abbott Laboratories | Surface-enhanced Raman spectroscopy immunoassay |
| DE69128350T2 (de) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| EP0598003B1 (en) | 1991-07-22 | 1999-02-10 | Kloehn Instruments, Ltd. | Substrate for surface-enhanced analytical procedures, and substrates prepared for specific procedures |
| JP2965502B2 (ja) | 1996-02-20 | 1999-10-18 | 株式会社京都第一科学 | 表面増強ラマン散乱測定による分析方法 |
| GB9810865D0 (en) | 1998-05-20 | 1998-07-22 | Zeneca Ltd | Nucleic acid sequence identification |
| ATE419528T1 (de) | 1999-04-28 | 2009-01-15 | Eidgenoess Tech Hochschule | Polyionische beschichtungen für analytische und sensor-vorrichtungen |
| EP2295954B1 (en) | 1999-10-06 | 2016-04-27 | Becton Dickinson and Company | Surface-enhanced spectroscopy-active composite nanoparticles |
| DE10050632A1 (de) | 2000-10-12 | 2002-04-18 | Stiftung Caesar | Verfahren zum Nachweis biologischer Moleküle |
| US7238477B2 (en) | 2001-09-24 | 2007-07-03 | Intel Corporation | Methods to increase nucleotide signals by Raman scattering |
| US7807348B2 (en) | 2002-03-20 | 2010-10-05 | Wisconsin Alumni Research Foundation | Optical imaging of nanostructured substrates |
| US7361313B2 (en) | 2003-02-18 | 2008-04-22 | Intel Corporation | Methods for uniform metal impregnation into a nanoporous material |
| US7192703B2 (en) | 2003-02-14 | 2007-03-20 | Intel Corporation, Inc. | Biomolecule analysis by rolling circle amplification and SERS detection |
| US20050148100A1 (en) | 2003-12-30 | 2005-07-07 | Intel Corporation | Methods and devices for using Raman-active probe constructs to assay biological samples |
| US7351591B2 (en) | 2004-03-30 | 2008-04-01 | Intel Corporation | Surface modification of metals for biomolecule detection using surface enhanced Raman scattering (SERS) |
| CA2563694C (en) | 2004-04-23 | 2014-01-07 | Oxonica, Inc. | Surface enhanced spectroscopy-active composite nanoparticles |
| CA2569863A1 (en) | 2004-06-07 | 2006-07-20 | Gryphon Analytics, Llc | Systems and method for fabricating substrate surfaces for sers and apparatuses utilizing same |
| US7483130B2 (en) | 2004-11-04 | 2009-01-27 | D3 Technologies, Ltd. | Metal nano-void photonic crystal for enhanced Raman spectroscopy |
| US7485471B1 (en) | 2004-12-17 | 2009-02-03 | Intel Corporation | Detection of enhanced multiplex signals by surface enhanced Raman spectroscopy |
| US7355704B2 (en) | 2005-06-13 | 2008-04-08 | Solaris Nanosciences, Inc. | Chemical and biological sensing using metallic particles in amplifying and absorbing media |
| US20070134815A1 (en) | 2005-07-11 | 2007-06-14 | Danielle Chamberlin | Sensitivity enhancement of POCT devices using gold and silver nanoparticles on substrates containing nanostructures or nanoparticles that interact with labeling particles |
| US7651863B2 (en) | 2005-07-14 | 2010-01-26 | 3M Innovative Properties Company | Surface-enhanced spectroscopic method, flexible structured substrate, and method of making the same |
| EP1948829A4 (en) | 2005-11-15 | 2009-08-26 | Becton Dickinson Co | SERS-BASED PROCEDURES FOR THE DETECTION OF BIOLOGICAL SUBSTANCES |
| GB0524580D0 (en) * | 2005-12-01 | 2006-01-11 | Sphere Medical Ltd | Sensor |
| GB0606088D0 (en) | 2006-03-27 | 2006-05-03 | E2V Biosensors Ltd | Improved serrs substrate |
| EP2755031B1 (en) | 2007-03-20 | 2017-05-03 | Becton, Dickinson and Company | Assay using surface-enhanced raman spectroscopy (sers)-active particles |
| EP2149050A2 (en) | 2007-04-27 | 2010-02-03 | The Regents Of The University Of California | Device and methods for detection of airborne agents |
| KR100892629B1 (ko) | 2007-06-29 | 2009-04-08 | 한국과학기술원 | 표면 증강 라만 분광용 광 센서 |
| JP2009031023A (ja) | 2007-07-25 | 2009-02-12 | Keio Gijuku | 表面増強ラマン分光分析用基板の作成方法、マイクロｔａｓの製造方法、及び、マイクロｔａｓ |
| US20100055803A1 (en) | 2008-08-29 | 2010-03-04 | Kwangyeol Lee | Method and apparatus for detecting molecules |
| US8947657B2 (en) * | 2008-09-08 | 2015-02-03 | Lawrence Livermore National Security, Llc | Methods for isolation and viability assessment of biological organisms |
| US20100136551A1 (en) * | 2008-10-10 | 2010-06-03 | Hansang Cho | Microfluidic platform and related methods and systems |
| RU2542386C2 (ru) * | 2009-12-11 | 2015-02-20 | Корея Рисерч Инститьют Оф Кемикал Текнолоджи | Димерная окклюдантная наноструктура, меченная молекулой, активной в отношении рамановского рассеяния, локализованной в межчастичном соединении, ее использование и способ ее получения |
| TWI487910B (zh) * | 2010-09-07 | 2015-06-11 | 國立成功大學 | 倒多角錐陣列型免標定病毒檢測基板、系統及方法 |
-
2012
- 2012-11-02 EP EP12790972.9A patent/EP2773958B1/en not_active Not-in-force
- 2012-11-02 DK DK12790972.9T patent/DK2773958T3/en active
- 2012-11-02 IN IN1168KON2014 patent/IN2014KN01168A/en unknown
- 2012-11-02 WO PCT/IB2012/056108 patent/WO2013065016A1/en not_active Ceased
- 2012-11-02 BR BR112014010696A patent/BR112014010696A2/pt not_active Application Discontinuation
- 2012-11-02 CN CN201280065543.0A patent/CN104380105B/zh not_active Expired - Fee Related
- 2012-11-02 US US14/355,765 patent/US9518986B2/en active Active
-
2014
- 2014-05-12 ZA ZA2014/03386A patent/ZA201403386B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013065016A1 (en) | 2013-05-10 |
| US20140302492A1 (en) | 2014-10-09 |
| IN2014KN01168A (cg-RX-API-DMAC7.html) | 2015-10-16 |
| ZA201403386B (en) | 2016-02-24 |
| BR112014010696A2 (pt) | 2017-04-25 |
| US9518986B2 (en) | 2016-12-13 |
| EP2773958B1 (en) | 2017-11-29 |
| CN104380105B (zh) | 2017-04-12 |
| EP2773958A1 (en) | 2014-09-10 |
| CN104380105A (zh) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2773958T3 (en) | Method for identifying an analyte in a biological sample | |
| Wu et al. | Challenges and solutions in developing ultrasensitive biosensors | |
| Hartjes et al. | Extracellular vesicle quantification and characterization: common methods and emerging approaches | |
| JP7079092B2 (ja) | サンプル分析のためのデバイスおよび方法 | |
| Choudhary et al. | Development of a point-of-care SPR sensor for the diagnosis of acute myocardial infarction | |
| Dey et al. | Single-molecule optical biosensing: recent advances and future challenges | |
| Jain | The role of nanobiotechnology in drug discovery | |
| JP2022058772A (ja) | 試料分析のためのデバイスおよび方法 | |
| Citartan et al. | Label-free methods of reporting biomolecular interactions by optical biosensors | |
| Langer et al. | Protein analysis by time-resolved measurements with an electro-switchable DNA chip | |
| Niedzwiecki et al. | Sampling a biomarker of the human immunodeficiency virus across a synthetic nanopore | |
| Zhu et al. | Frequency shift surface-enhanced Raman spectroscopy sensing: An ultrasensitive multiplex assay for biomarkers in human health | |
| Qi et al. | Ultrasensitive electrogenerated chemiluminescence peptide-based method for the determination of cardiac troponin I incorporating amplification of signal reagent-encapsulated liposomes | |
| Li et al. | Ultrasensitive detection of exosomes using an optical microfiber decorated with plasmonic MoSe2-supported gold nanorod nanointerfaces | |
| Huo et al. | ATP-responsive strand displacement coupling with DNA origami/AuNPs strategy for the determination of microcystin-LR using surface-enhanced Raman spectroscopy | |
| Hasanzadeh et al. | Optical immunosensing of effective cardiac biomarkers on acute myocardial infarction | |
| CN106461640A (zh) | 包含其中具有可控移动性的金属颗粒探针偶合的支持的脂质双层的人工细胞膜及使用其分析分子间相互作用的方法 | |
| Guan et al. | Glass capillary-based nanopores for single molecule/single cell detection | |
| Wang et al. | Versatile biosensing toolkit using an electronic particle counter | |
| Horne et al. | Detection of protein oligomers with nanopores | |
| Zhou et al. | Label-free optical imaging of nanoscale single entities | |
| Zhang et al. | Large Laser Spot-Swift Mapping Surface-Enhanced Raman Scattering on Ag Nanoparticle Substrates for Liquid Analysis in Serum-Based Cancer Diagnosis | |
| Wu et al. | Low-Temperature Substrate: Detection of Viruses on Cold Chain Food Packaging Based on Surface-Enhanced Raman Spectroscopy | |
| Morris et al. | The Physical Characterization of Extracellular Vesicles for Function Elucidation and Biomedical Applications: A Review | |
| Jahani et al. | Ultrasensitive detection of attomolar neurofilament light chain using gold nanoparticle-assisted CRISPR-Cas12a enhanced fluorescent assay |